Funding Daily Summary
Funding Daily Summary: What Happened on November 11, 2026
VectorY secures €74.5 million for ALS gene therapy trial
Neobe raised $6.8 million for an engineered-bacteria cancer therapy, while Oyster closed a $60 million round for tau-degrader programs.
Today in brief
VectorY secured €74.5 million to fund its ALS gene therapy trial through final results and support other programs.1 Neobe raised $6.8 million for preclinical work on its engineered-bacteria cancer program, and Oyster closed a $60 million round for tau-degrader development.23
VectorY raises €74.5 million for ALS trial
VectorY’s financing includes a €30 million loan from the European Investment Bank, backed by the European Commission’s InvestEU program.1 The proceeds are intended to fund VTx-002 through final results from its Phase 1/2 PIONEER-ALS trial.1
The trial began dosing in February 2026 and plans to enroll 36 participants, up from 12 after VectorY cited fast recruitment and clinical-site activation.1 It tests two doses of a one-time gene therapy designed to prompt cells in the central nervous system to produce antibodies against abnormal TDP-43.1 Safety and tolerability are the trial’s main focus. Investigators are also monitoring biomarkers and measures of disease progression.1
The financing will also support VTx-003, a preclinical program targeting mutant huntingtin, and earlier programs for frontotemporal dementia and Alzheimer’s disease.1 VTx-002’s safety and potential clinical benefit remain unproven.1
Neobe raises $6.8 million for engineered-bacteria cancer program
Neobe raised a $6.8 million seed round led by ARC Ventures to advance NEO22 through preclinical development.2 The company is developing nonpathogenic bacteria that produce enzymes inside tumors to break down part of the surrounding matrix.2
In a 2026 mouse study, the treatment reduced tumor stiffness and increased immune-cell entry.2 Neobe reported that one dose combined with immunotherapy fully regressed tumors in a model of treatment-resistant triple-negative breast cancer. Mice later resisted re-exposure to the cancer.2 The results are preclinical, and responses varied with tumor stiffness and the composition of the surrounding matrix.2
Neobe plans to seek an investigational new drug application in 2028 and said its total funding now exceeds $10.5 million.2 Laura Chow joined as chief medical officer, responsible for clinical development.2
Oyster closes $60 million round for tau-degrader work
Oyster Therapeutics closed a $60 million Series A-2 round led by 4BIO Capital, with Eli Lilly among the new investors. The company also adopted Oyster as its trading name.3 The financing will support an oral degrader designed to remove pathological tau while preserving healthy forms of the protein.34
Oyster’s SELFTAC platform uses a reversible linker intended to let smaller components cross cell membranes before joining into an active degrader.4 Oyster says the approach could help degraders reach the brain. It still needs to demonstrate adequate brain exposure, selective tau clearance and clinical benefit.4
A sponsored research partnership with Massachusetts General Hospital will use patient-derived neuronal cell lines and methods to detect toxic forms of tau.3 The financing will also support development of SELFTAC.3
Also published
- Latest News on TechBio Revolution 🪴 MetaphysicalCells
- UK's Oyster Tx rebrands and raises $60m for Alzheimer's R&D pharmaphorum
- Neobe Plans to Stop Cancer Using Engineered Bacteria Inside Precision Medicine
- London biotech Oyster harvests $60M for tau-targeting brain drugs BioPharma Dive